Arch Therapeutics, Inc. (ARTH)
USD 0.16
(-10.93%)
USD 0.16
(-10.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.04 Million USD | -11.12% |
| 2022 | 5.67 Million USD | -10.84% |
| 2021 | 6.36 Million USD | 18.47% |
| 2020 | 5.37 Million USD | -15.71% |
| 2019 | 6.37 Million USD | -14.47% |
| 2018 | 7.44 Million USD | 2.02% |
| 2017 | 7.3 Million USD | 20.69% |
| 2016 | 6.05 Million USD | 10.81% |
| 2015 | 5.46 Million USD | 18.4% |
| 2014 | 4.61 Million USD | 164.29% |
| 2013 | 1.74 Million USD | 4666.26% |
| 2012 | 36.61 Thousand USD | 626.84% |
| 2011 | 5037.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.51 Million USD | 12.77% |
| 2024 Q2 | 887.05 Thousand USD | -41.52% |
| 2024 Q3 | 1.03 Million USD | 16.26% |
| 2023 Q1 | 1.26 Million USD | -12.36% |
| 2023 Q2 | 1.42 Million USD | 12.58% |
| 2023 FY | 5.04 Million USD | -11.12% |
| 2023 Q3 | 1 Million USD | -29.11% |
| 2023 Q4 | 1.34 Million USD | 33.3% |
| 2022 Q2 | 1.73 Million USD | 15.95% |
| 2022 FY | 5.67 Million USD | -10.84% |
| 2022 Q4 | 1.44 Million USD | 44.83% |
| 2022 Q1 | 1.49 Million USD | -12.43% |
| 2022 Q3 | 996.06 Thousand USD | -42.64% |
| 2021 Q1 | 1.26 Million USD | -6.77% |
| 2021 Q4 | 1.71 Million USD | 2.54% |
| 2021 FY | 6.36 Million USD | 18.47% |
| 2021 Q2 | 1.75 Million USD | 38.59% |
| 2021 Q3 | 1.66 Million USD | -4.71% |
| 2020 Q3 | 1.24 Million USD | 7.55% |
| 2020 Q1 | 1.61 Million USD | 6.25% |
| 2020 Q2 | 1.15 Million USD | -28.71% |
| 2020 Q4 | 1.35 Million USD | 9.11% |
| 2020 FY | 5.37 Million USD | -15.71% |
| 2019 Q3 | 1.57 Million USD | 4.31% |
| 2019 Q4 | 1.52 Million USD | -3.05% |
| 2019 FY | 6.37 Million USD | -14.47% |
| 2019 Q1 | 1.76 Million USD | -20.85% |
| 2019 Q2 | 1.5 Million USD | -14.73% |
| 2018 Q2 | 2.01 Million USD | 27.27% |
| 2018 FY | 7.44 Million USD | 2.02% |
| 2018 Q4 | 2.23 Million USD | 37.85% |
| 2018 Q3 | 1.62 Million USD | -19.55% |
| 2018 Q1 | 1.58 Million USD | -15.9% |
| 2017 Q4 | 1.88 Million USD | 2.19% |
| 2017 FY | 7.3 Million USD | 20.69% |
| 2017 Q1 | 1.37 Million USD | -22.87% |
| 2017 Q2 | 2.2 Million USD | 60.19% |
| 2017 Q3 | 1.84 Million USD | -16.47% |
| 2016 Q1 | 1.27 Million USD | -19.86% |
| 2016 FY | 6.05 Million USD | 10.81% |
| 2016 Q4 | 1.78 Million USD | 2.95% |
| 2016 Q3 | 1.73 Million USD | 38.09% |
| 2016 Q2 | 1.25 Million USD | -1.94% |
| 2015 Q2 | 1.25 Million USD | -1.14% |
| 2015 FY | 5.46 Million USD | 18.4% |
| 2015 Q1 | 1.27 Million USD | -8.58% |
| 2015 Q4 | 1.59 Million USD | 19.3% |
| 2015 Q3 | 1.33 Million USD | 6.57% |
| 2014 FY | 4.61 Million USD | 164.29% |
| 2014 Q4 | 1.38 Million USD | 21.19% |
| 2014 Q3 | 1.14 Million USD | -11.52% |
| 2014 Q2 | 1.29 Million USD | 65.96% |
| 2014 Q1 | 780.67 Thousand USD | -18.77% |
| 2013 Q3 | 494.79 Thousand USD | 10784.21% |
| 2013 Q4 | 961.05 Thousand USD | 94.23% |
| 2013 FY | 1.74 Million USD | 4666.26% |
| 2013 Q2 | 4546.00 USD | 259.37% |
| 2013 Q1 | 1265.00 USD | -93.89% |
| 2012 Q2 | 9108.00 USD | 949.31% |
| 2012 Q4 | 20.71 Thousand USD | 250.14% |
| 2012 FY | 36.61 Thousand USD | 626.84% |
| 2012 Q1 | 868.00 USD | -82.57% |
| 2012 Q3 | 5917.00 USD | -35.04% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | 5037.00 USD | 0.0% |
| 2011 Q3 | 19.00 USD | 0.0% |
| 2011 Q4 | 4981.00 USD | 26115.79% |
| 2011 Q2 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -277.559% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 82.939% |
| Nascent Biotech, Inc. | 2.22 Million USD | -126.113% |
| Rebus Holdings, Inc. | 664 Thousand USD | -659.344% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 86.466% |
| Qrons Inc. | 643.67 Thousand USD | -683.319% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1194.272% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 91.222% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1113.55% |
| Skye Bioscience, Inc. | 13.54 Million USD | 62.783% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 94.19% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2.524% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1826.459% |
| SQZ Biotechnologies Company | 85.61 Million USD | 94.111% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -72.896% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -235.711% |
| Mesoblast Limited | 5.9 Million USD | 14.571% |
| Marizyme, Inc. | 19.23 Million USD | 73.794% |
| Genus plc | 147.7 Million USD | 96.586% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 42.569% |
| Pharming Group N.V. | 225.49 Million USD | 97.764% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -146.109% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -275.839% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 39.537% |
| ContraFect Corporation | 56.88 Million USD | 91.137% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -14.367% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -240.966% |
| IMV Inc. | 37.7 Million USD | 86.629% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -80.695% |
| MultiCell Technologies, Inc. | 567.42 USD | -888491.167% |
| ONE Bio Corp. | 6.44 Million USD | 21.755% |
| Accustem Sciences Inc. | 3.74 Million USD | -34.583% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 94.133% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -847.82% |
| Q BioMed Inc. | 3.43 Million USD | -46.715% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 79.599% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -91.894% |
| Biomind Labs Inc. | 994.18 Thousand USD | -407.155% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 94.924% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -186.532% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 24.947% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -170.442% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 20268.176% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 68.507% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -174.757% |
| GB Sciences, Inc. | 1.42 Million USD | -254.946% |
| Alpha Cognition Inc. | 9.7 Million USD | 48.05% |
| HST Global, Inc. | 140.9 Thousand USD | -3478.278% |
| CSL Limited | 3.44 Billion USD | 99.854% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -348.218% |
| Halberd Corporation | 74.84 Thousand USD | -6636.918% |
| Enzolytics Inc. | 2.17 Million USD | -131.339% |
| Agentix Corp. | 1.37 Million USD | -267.561% |
| Resverlogix Corp. | 12.71 Million USD | 60.336% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -38.111% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.671% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -382.954% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -109.654% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -219.247% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -48.079% |
| AVAX Technologies, Inc. | 7.31 Million USD | 31.028% |
| Zenith Capital Corp. | 8.94 Million USD | 43.62% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.389% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -28842.334% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -105.352% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2839.813% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -162.483% |
| Kadimastem Ltd | 2.41 Million USD | -109.204% |
| Helix BioMedix, Inc. | 1.97 Million USD | -155.677% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 53.602% |
| BioStem Technologies, Inc. | 22.97 Million USD | 78.054% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2678.215% |
| LadRx Corporation | 3.81 Million USD | -32.275% |
| Cell Source, Inc. | 4.32 Million USD | -16.57% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -445.965% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -445.965% |
| NovAccess Global Inc. | 2.46 Million USD | -104.399% |
| Affymax, Inc. | 39.38 Million USD | 87.198% |
| Itoco Inc. | 919.14 Thousand USD | -448.559% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -18.961% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -350.585% |
| Mobile Lads Corp. | 554.54 Thousand USD | -809.22% |
| CytoDyn Inc. | 18.05 Million USD | 72.079% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -19932.755% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -2191.026% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -255.126% |
| SYBLEU INC | 160.87 Thousand USD | -3034.118% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -177.597% |
| International Stem Cell Corporation | 5.27 Million USD | 4.344% |
| Bioxytran, Inc. | 3.82 Million USD | -31.986% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -9477.987% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -24685.155% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 86.097% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -211.622% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -585.214% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -62.071% |
| Neutra Corp. | 243.82 Thousand USD | -1967.929% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 71.117% |
| PureTech Health plc | 144.59 Million USD | 96.513% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 75.393% |
| IXICO plc | 4.7 Million USD | -7.118% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 42.685% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 95.718% |
| CSL Limited | 3.89 Billion USD | 99.87% |
| Cellectis S.A. | 97.32 Million USD | 94.819% |